Results 131 to 140 of about 655,557 (182)

Disease characteristics, treatment, and outcomes in Chinese chronic lymphocytic leukemia patients following BTK inhibitor discontinuation: a multicenter real-world study. [PDF]

Front Med (Lausanne)
Yan Y, Wang W, Yan X, Xu H, Wu D, Wang T, Liu W, Huang W, An G, Zou D, Lin J, Fu Y, Qiu L, Yi S.   +13 more
europepmc   +1 more source

A new era in chronic spontaneous urticaria: FDA approval of the oral BTK inhibitor remibrutinib. [PDF]

Ann Med Surg (Lond)
Jan M, Qazi K, Noor A, Naveed M, Khalid M, Waafira A.   +5 more
europepmc   +1 more source

Is Brukinsa (Zanubrutinib) a Safer Bruton's Tyrosine Kinase (BTK) Inhibitor in Relapsed or Refractory Chronic Lymphocytic Leukemia? A Systematic Review and Meta-Analysis. [PDF]

Pharmaceuticals (Basel)
Hetta HF, Salama A, Aljuaid TA, Mojmami YT, Alotibi RS, Alqabaly AM, Aldosari NA, Alshahri SA, Asiri WIA, Alamri RS, Alanazi FA, Alenazi MSA, Albuhayri MH, Ramadan YN, Sayad R.   +14 more
europepmc   +1 more source

Real-World Selection of Venetoclax-Obinutuzumab Versus BTK Inhibitor Therapy for Treatment-Naïve Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. [PDF]

Eur J Haematol
Tidswell R, Owen C, Shafey M, Perry S, Cox-Kennett N, Sterrett R, Peters A, Puckrin R.   +7 more
europepmc   +1 more source

Mosunetuzumab plus polatuzumab vedotin for relapsed/refractory MCL after BTK inhibitor therapy: a phase 2 study.

Blood
Budde LE, Kamdar M, Assouline SE, Chavez JC, Ghosh N, Ollila TA, Hodson DJ, Modi D, Bastos-Oreiro M, Naik SG, Nakhoda SK, Lee Batlevi C, Wang J, Makadia S, Kwan A, Penuel E, Jing J, Wu H, Ead W, Pham S, To I, Wei MC, Wang ML.   +22 more
europepmc   +1 more source

BTK inhibitor ibrutinib reduces LPS-induced inflammation in C8-B4 microglia. [PDF]

EXCLI J
Das D, Mali AS, Greco D, Michalicková D, Novotný J, Slanar O.   +5 more
europepmc   +1 more source

Corrigendum to "Tumor-homing exosomes enable targeted delivery of siRNA and isoimperatorin for overcoming BTK inhibitor resistance in DLBCL" [Mater. Today Bio (35) 102267]. [PDF]

Mater Today Bio
Sun R, Yang Y, Zhang B, Chen J, Wang Y, Jiang Z, Zhang L, Ashrafizadeh M, Sethi G, Shen J, Chi Z.   +10 more
europepmc   +1 more source

First-in-Human Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Ascending Oral Doses of BIIB091, an Oral BTK Inhibitor, in Healthy Adult Participants. [PDF]

Drug Des Devel Ther
Tsai HH, Gu Y, Riester K, Chu SS, Bame E, Arefayene M, Kam JLYL, Coppell A, Hanna J, Hopkins BT, Scaramozza M.   +10 more
europepmc   +1 more source

BTK-Inhibitor Loaded Polymeric Nanoparticles Alleviate Systemic Lupus Erythematosus by Targeting Elimination of Autoreactive BAFFR^high B Cells. [PDF]

Int J Mol Sci
Zhang Y, Wen J, Jiang B, Jiang H, Xu J, Tao J.   +5 more
europepmc   +1 more source

Correction: Predictors and responses to varying durations of BTK inhibitor bridging therapy before anti-CD19 CAR-T cell therapy in patients with relapsed/refractory DLBCL. [PDF]

Front Immunol
Wang J, Cui R, Qi Y, Mu J, Li X, Li Q, Deng Q.   +6 more
europepmc   +1 more source